Skip to main content
. 2023 Apr 13;25:60. doi: 10.1186/s13075-023-03036-4

Fig. 4.

Fig. 4

Association between trough plasma ozoralizumab concentration and ACR20 or ACR50 response in the OHZORA trial (A) and the NATSUZORA trial (B) using receiver operating characteristic analysis. ACR20/50 ≥ 20%/50% improvement according to the American College of Rheumatology criteria